arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Xencor, Inc.

XNCR Health Care Biotechnology: Pharmaceutical Preparations
$25.84
▲ +3.6% Today
as of Oct 23, 09:24 ET
Last 30 days +5.34% Sep 14 → Oct 22
$22.61 $23.48 $24.35 $25.21 $26.08 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$25.18
High
$26.12
Low
$24.71
Volume
$936,276
Avg Vol
$971,048
Mkt Cap
$1.8B
P/E (TTM)
—
Beta
—
52w High
$30.61
52w Low
$10.38
Div Yield
—
Shares Out
$74M

Recent Press Releases & News last 60 days · 6 items

Oct 19 · 23:19 Simply Wall St.
Is Xencor (XNCR) A Bargain After Its XmAb819 Phase 1 Update?
Oct 19 · 11:01 PR Business Wire
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Sep 25 · 17:33 MT Newswires
Xencor's XmAb819 Data Could Support Registrational Path, Wedbush Says
▸ Show all 6 press releases & news Free account →

XNCR earnings at a glance

Xencor, Inc. (XNCR) is scheduled to report earnings on Wednesday, November 4, 2026 — in 12 days. Analysts expect earnings per share of -$0.35, compared with -$0.08 in the same quarter last year (-337%). The options market is pricing a move of about ±15.6% after the report, a range of roughly $21.81 to $29.87 from today's $25.84. Over its last 6 reports the stock rose the next day 3 times and fell 3, moving ±5.7% on average; after the most recent report on Aug 5, 2026 it moved +0.8%. That means options currently expect more movement than XNCR has typically delivered. XNCR beat the consensus EPS estimate in 4 of its last 6 reported quarters. Implied volatility is currently 132%. The share price of $25.84 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$10
$31
76% of range
Avg surprise (last 6)
+19.8%
Avg reaction (last 6)
+2.3%
50% positive
Latest IV / EM
132%
EM ±15.6% · $25 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.71$-1.30$-0.90$-0.49$-0.08 Actual $-1.02Actual $-0.37Actual $-0.40Actual $-1.20Actual $-1.09Actual $-0.72Actual $-0.66Est $-0.63Actual $-0.41Est $-0.78Actual $-0.08Est $-0.72Actual $-0.09Est $-0.64Actual $-1.71Est $-0.65Actual $-0.29Est $-0.82 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-129M$-83M$-38M$8M$54M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Wed Aug 5, 2026Jun/2026 $-0.29 $-0.82 +64.6% -100.0% +0.8% earnings
Wed May 6, 2026Mar/2026 $-1.71 $-0.65 -163.1% -159.1% -5.4% earnings
Wed Feb 25, 20268K 2026-02-25 $-0.09 $-0.64 +85.9% — +13.1% earnings
Wed Nov 5, 2025Sep/2025 $-0.08 $-0.72 +88.9% — -2.6% earnings
Wed Aug 6, 2025Jun/2025 $-0.41 $-0.78 +47.4% — -2.3% earnings
Wed May 7, 2025Mar/2025 $-0.66 $-0.63 -4.8% — +10.1% earnings
Mon Sep 30, 2024Sep 2024 $-0.72 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.09 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.20 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.40 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.37 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.02 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Wed Nov 4, 2026Sep/2026OTHER -$0.35-$0.08 -337.5%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$51M$5M—$21M$44M$33M—$18M
Cost of revenue————————
Gross profit————————
Operating income$-37M$-78M—$-48M$-33M$-43M—$-55M
Net income$-22M$-129M—$-6M$-31M$-49M—$-46M
EPS (diluted)$-0.29$-1.71—$-0.08$-0.41$-0.66—$-0.72

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$45M$14M$54M$28M$44M$40M$41M$29M
Inventory————————
Total current assets$523M$483M$600M$518M$513M$521M$578M$590M
Total assets$725M$737M$875M$869M$879M$905M$952M$1000M
Long-term debt$78M$82M$76M$88M$95M$102M$115M$128M
Total liabilities$222M$221M$240M$243M$259M$265M$278M$294M
Total equity$503M$516M$636M$625M$620M$640M$678M$706M

Implied volatility — last 90 days

55%280%505%730%955% Jun 15 — IV 577% · EM ±41.8%Jun 16 — IV 708% · EM ±41.8%Jun 17 — IV 956% · EM ±39.9%Jun 22 — IV 173% · EM ±36.2%Jun 24 — IV 176% · EM ±35.3%Jun 25 — IV 177% · EM ±34.6%Jun 26 — IV 180% · EM ±34.4%Jul 01 — IV 198% · EM ±33.2%Jul 09 — IV 171% · EM ±20.2%Jul 10 — IV 184% · EM ±20.3%Jul 13 — IV 124% · EM ±10.4%Jul 14 — IV 466% · EM ±33.7%Jul 15 — IV 141% · EM ±8.3%Jul 16 — IV 809% · EM ±33.8%Jul 20 — IV 124% · EM ±29.2%Jul 21 — IV 95% · EM ±22.0%Jul 22 — IV 122% · EM ±27.9%Jul 23 — IV 133% · EM ±29.9%Jul 24 — IV 126% · EM ±27.8%Jul 27 — IV 131% · EM ±27.3%Jul 28 — IV 83% · EM ±17.0%Jul 29 — IV 130% · EM ±26.1%Jul 30 — IV 65% · EM ±12.8%Jul 31 — IV 85% · EM ±16.2%Aug 06 — IV 99% · EM ±16.0%Aug 07 — IV 101% · EM ±15.9%Aug 10 — IV 61% · EM ±8.5%Aug 11 — IV 57% · EM ±7.6%Aug 12 — IV 61% · EM ±7.7%Aug 13 — IV 55% · EM ±6.5%Aug 14 — IV 55% · EM ±6.1%Aug 17 — IV 69% · EM ±5.7%Aug 18 — IV 264% · EM ±19.1%Aug 19 — IV 314% · EM ±18.5%Aug 20 — IV 585% · EM ±24.4%Aug 24 — IV 83% · EM ±17.2%Aug 25 — IV 75% · EM ±15.3%Aug 26 — IV 82% · EM ±16.4%Aug 27 — IV 71% · EM ±13.8%Aug 28 — IV 72% · EM ±13.7%Aug 31 — IV 153% · EM ±27.2%Sep 01 — IV 122% · EM ±21.1%Sep 02 — IV 105% · EM ±17.5%Sep 03 — IV 158% · EM ±25.5%Sep 04 — IV 126% · EM ±19.6%Sep 07 — IV 142% · EM ±19.6%Sep 08 — IV 96% · EM ±12.7%Sep 09 — IV 145% · EM ±18.1%Sep 10 — IV 154% · EM ±18.2%Sep 11 — IV 180% · EM ±19.9%Sep 14 — IV 189% · EM ±15.8%Sep 15 — IV 309% · EM ±22.3%Sep 16 — IV 370% · EM ±21.8%Sep 17 — IV 297% · EM ±12.4%Sep 21 — IV 103% · EM ±21.4%Sep 22 — IV 91% · EM ±18.6%Sep 23 — IV 100% · EM ±20.1%Sep 24 — IV 110% · EM ±21.6%Sep 25 — IV 121% · EM ±23.1%Sep 28 — IV 114% · EM ±20.2%Sep 29 — IV 106% · EM ±18.3%Sep 30 — IV 124% · EM ±20.7%Oct 01 — IV 110% · EM ±17.9%Oct 02 — IV 102% · EM ±15.9%Oct 05 — IV 114% · EM ±15.9%Oct 06 — IV 114% · EM ±15.1%Oct 07 — IV 139% · EM ±17.4%Oct 08 — IV 132% · EM ±15.6%

Sector peers

LKFT
Lakefront Biotherapeutics
$1.9B $31.40+2.1%
AGIO
Agios Pharmaceuticals, Inc.
$1.9B $37.19+1.5%
GPCR
Structure Therapeutics Inc.
$1.9B $21.93-4.2%
MRVI
Maravai LifeSciences Holdings, Inc.
$1.9B $7.07-1.8%
HCM
HUTCHMED (China) Limited
$2.0B $14.28-3.1%
QURE
uniQure N.V.
$1.6B $23.11+1.7%

XNCR earnings FAQ

When is XNCR's next earnings date?

Xencor, Inc. is expected to report on November 4, 2026.

What is XNCR's expected move for earnings?

Options currently price a move of about ±15.6%, or $4.03 per share either way from $25.84.

How does XNCR stock usually react to earnings?

Across the last 6 reports the average next-day move was ±5.7%, up 3 times and down 3 times.

What EPS are analysts expecting from Xencor, Inc.?

The consensus estimate is -$0.35 per share, versus -$0.08 a year ago.

What is XNCR's implied volatility?

XNCR's at-the-money implied volatility is about 132% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in